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RESPONDING TO DRUG DRIVING IN EUROPE  
New EMCDDA policy briefing underlines need for enforceable and evidence-based laws  
 
(18.9.2009, LISBON) Many of the accidents and deaths that occur on European roads are caused by drivers 
whose performance is impaired by a psychoactive substance. Alcohol alone is estimated to account for up to 
10 000 road deaths a year in the EU, one quarter of all road deaths (1). But, says the EMCDDA, no comparable 
figures are available for road accidents relating to illcit drugs and psychoactive medicines. This means that, 
with no clear picture of the problem, tailoring responses will prove difficult.  
The need to gather evidence on drugs and driving, as a basis for effective responses in prevention and 
enforcement, is underlined in the latest edition of Drugs in focus, the EMCDDA’s policy briefing. In it, the 
agency summarises key issues now facing policymakers in this area and outlines innovative developments.  
‘Reducing the loss of life caused by driving under the influence of psychoactive substances requires measures 
that are based on a scientific understanding of this complex phenomenon’, says EMCDDA Director Wolfgang 
Götz. ‘The challenge to legislators is to design sound and effective laws that can be enforced, and that give a 
clear message to the public’. 
The release of the publication to policymakers is timely. At the start of the European road safety programme in 
2003, it was estimated that over 40,000 people were dying on Europe’s roads every year. The programme set 
the ambitious target of halving the number of road deaths in Europe by the end of 2010. Next year the 
European Commission’s DRUID project (Driving under the influence of alcohol, drugs and medicines), which 
provides scientific support to this target, also comes to a close (2). DRUID aims to provide a solid basis for 
harmonised, EU-wide regulations for driving under the influence of alcohol, drugs and medicines. 
Policy considerations presented in today’s briefing include:  
 
• Surveys on the prevalence of drugs in drivers should be carried out in all EU Member States. At minimum, 
testing all drivers involved in a fatal accident for drugs and alcohol would provide an important source of 
information for monitoring the problem. Despite a European Commission recommendation in 2002 for such 
tests, few countries have adopted them and data remain scarce. 
• Studies undertaken in this field need to be comparable if results are to be compiled. The EMCDDA and the 
European Commission have contributed to new international guidelines on study design that take into 
account differences between countries’ legislation and testing policies. These provide over 100 
recommendations in the areas of behaviour, epidemiology and toxicology (3).  
• Legal definitions of driving under the influence of drugs differ among EU Member States. Eleven countries 
have adopted a ‘zero tolerance’ approach penalising any driving after drug taking. Eleven others only 
penalise when there is evidence that driving performance has been impaired. Seven countries use a tiered 
response using both approaches. The level at which a driver will be deemed in breach of the law should be 
clear for all stakeholders and the public. 
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• Psychoactive medicines, whether consumed legally or not, can impair driving skills. National laws and their 
enforcement need to strike a balance between concerns about ensuring road safety and the therapeutic 
needs of individuals; to this end, some countries have adopted a two-tier penalty system. Providing clear 
information, such as a pictogram, on psychoactive medicines that affect driving ability may prevent patients 
from driving while adversely affected. But this is currently reported by only five countries.  
• As yet there is no agreement on a reliable on-site saliva-testing device. The EU’s Rosita-2 project could not 
recommend any of the nine devices evaluated between 2003 and 2005 (4). In France, drivers are screened 
with saliva tests, but prosecution is based on a blood sample. For this reason, police experience 
considerable difficulty with the accurate and rapid identification of drug driving at the roadside. With no 
reliable testing device available, traffic police need more training in spotting signs of impairment due to 
drugs. Despite a call by the European Commission in 2002 for mandatory training for traffic police, by 2007 
only four countries (Belgium, Portugal, Sweden, UK) reported obligatory training in this area.  
• General messages that reach young cannabis users are unlikely to be listened to, or even noticed, by older 
users of psychoactive medicines and vice versa. Similarly, both groups may feel that warnings about alcohol 
do not apply to them. Thus, key audiences may not be hearing the message, or they may be ignoring it. 
Prevention efforts are more likely to succeed if they are tailored to specific substances and groups.  
After alcohol, cannabis and benzodiazepines are the psychoactive substances most prevalent among Europe’s 
driving population. Studies on the impact of psychoactive substances on driving performance suggest that while 
both illicit and therapeutic drugs can affect driving, the effects can vary greatly from substance to substance.  
Drugs in focus No 20 is available in 25 languages at  www.emcdda.europa.eu/publications/drugs-in-focus 
For a full range of EMCDDA products on drugs and driving, see http://www.emcdda.europa.eu/themes/driving 
 
Notes: 
 
(1) European road safety action programme (2003–2010): ‘Saving 20 000 lives on our roads: A shared responsibility’, see 
http://ec.europa.eu/transport/roadsafety_library/rsap/rsap_en.pdf                                                                                                                          
(2) A four-year €24m project launched in October 2006 and involving 21 European countries and 37 partners.                                                
See http://www.druid-project.eu  
(3) See Guidelines for research on drugged driving at http://www.emcdda.europa.eu/themes/driving. See also Drugnet 
Europe 57 and 60 http://www.emcdda.europa.eu/publications/drugnet                                                                   
(4) Rosita — http://www.rosita.org  
 
 
 
 
 
 
 
